Last C$0.07 CAD
Change Today 0.00 / 0.00%
Volume 30.0K
VPT On Other Exchanges
Symbol
Exchange
Venture
OTC US
As of 12:28 PM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

ventripoint diagnostics ltd (VPT) Snapshot

Open
C$0.07
Previous Close
C$0.07
Day High
C$0.07
Day Low
C$0.07
52 Week High
03/10/14 - C$0.17
52 Week Low
11/18/13 - C$0.03
Market Cap
12.6M
Average Volume 10 Days
122.3K
EPS TTM
C$-0.0098
Shares Outstanding
179.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VENTRIPOINT DIAGNOSTICS LTD (VPT)

Related News

No related news articles were found.

ventripoint diagnostics ltd (VPT) Related Businessweek News

No Related Businessweek News Found

ventripoint diagnostics ltd (VPT) Details

VentriPoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools to monitor patients with heart disease primarily in Canada and Europe. The company offers VentriPoint Diagnostic System that is used to generate critical shape and volume measurements of the right ventricle. Its VentriPoint Diagnostic System consists of commercial off-the-shelf computer and tracking system sensor, as well as patented and proprietary methods, and software. VentriPoint Diagnostics Ltd. is based in Calgary, Canada.

ventripoint diagnostics ltd (VPT) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $247.9K
Chief Financial Officer and Vice President
Total Annual Compensation: $72.6K
Compensation as of Fiscal Year 2013.

ventripoint diagnostics ltd (VPT) Key Developments

Ventripoint Diagnostics Ltd. Signs Distribution Agreement with Shandong Realcan Pharmaceuticals Co. Ltd

Ventripoint Diagnostics Ltd. announced that it has signed a distribution agreement with Shandong Realcan Pharmaceuticals Co. Ltd. to distribute its VMS heart analysis system in China. Ventripoint aims to seek regulatory approval from the China Food and Drug Administration for the VMS heart analysis system, which measures right ventricle function, according to Ventripoint. Once CFDA approval has been granted, the product will be deployed on a pay per use model after a reimbursement fee is established for the procedure.

VentriPoint Diagnostics Ltd. to Amend its By-Laws

VentriPoint Diagnostics Ltd. at its annual general and special meeting of the shareholders to be held on September 18, 2014, is to consider, and if thought fit, approve, adopt and ratify, with or without modification, an ordinary resolution approving the amendments to the By-laws of the Corporation.

VentriPoint Diagnostics Ltd., Annual General Meeting, Sep 18, 2014

VentriPoint Diagnostics Ltd., Annual General Meeting, Sep 18, 2014., at 11:00 Pacific Standard Time. Location: Davis LLP, Suite 2800. Agenda: To receive the financial statements of the corporation for the year ended December 31, 2013 and the report of the auditors thereon; to fix the number of directors at four and to elect directors; to appoint auditors and authorize the directors to fix their remuneration; to consider the incentive stock option plan; to consider the changes to the deferred share unit plan; to consider an increase of 1,500,000 units in the number of deferred share units available under the corporation's DSU Plan; to re-approve the amendment to the corporation's articles permitting the consolidation of the corporation's issued and outstanding shares, on a ratio ranging from a five-to-one to ten-to-one basis; to consider the amendments to the By-laws of the corporation, as more particularly set forth in the accompanying Information Circular; and to transact such other business as may properly be brought before the meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VPT:CN C$0.07 CAD 0.00

VPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VPT.
View Industry Companies
 

Industry Analysis

VPT

Industry Average

Valuation VPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 130.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 136.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENTRIPOINT DIAGNOSTICS LTD, please visit www.ventripoint.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.